Optimization formula gastroretentive tablet of ranitidine HCl with floating system

T.N. Saifullah Sulaiman, Achmad Fudholi, A. Kharis Nugroho


Ranitidine  HCl  is  an  H-2  receptor  antagonists  for  the  treatment  of  peptic gastric  secretion  with  a  small  bioavailability,  so  that  should  be  developed  in  a sustained  release  dosage  form  are  retained  in  the  stomach.  Ranitidine  HCl floating  tablet  was  formulation  by  effervescent  system.  Simplex  lattice  design was  applied  to  optimize  the  formula  of  ranitidine  HCl  floating  tablet  by varying levels of Methocel K15M 100-185 mg, sodium bicarbonate 15-100 mg, and  citric  acid0-85 mg.  The  Optimum  formula  determined  by  superimposed contour  plot  from  various  parameters:  flowability  of  granules,  physical properties of tablet and drug release using Design-Expert®program. Based on superimposed  contour  plot obtained  optimum  formula  for  the  area  in  the  range of Methocel K15M 100-145 mg, sodium bicarbonate 20-80 mg and citric acid 25-80 mg.

Key words: Ranitidine HCl, Gastroretentive, Simplex lattice design


Full Text:



Anonim, 2000, Using METHOCEL Cellulose Ethers for Controlled Release of Drugs in Hydrophilic Matrix Systems, The Dow Chemical Company, USA, 8.

Asif, M., Yasir, M, Bhattacharya, A. and Bajpai, M., 2010, Formulation and evaluation of gastroretentive dosage form for fluvastatin sodium, Pharm. Globale (IJCP), 4 (08), 1-4.

Basit, A., Lacey, L., 2001, Colonic metabolism of ranitidin HCl: implications for its delivery and absorption, Int. J. Pharm., 227 (1-2), 157-165.

Bolton, S. and Bon, C., 2004, Pharmaceutical Statistic: Practical and Clinical Applications, 4th Ed., 590-620, Marcel Dekker, Inc., New York.

Cremer K., 1997, Drug delivery: Gastro- remaining dosage forms. Pharm. J.,259, 108-113

Grant S. 1989, Ranitidin HCl: an updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer and other allied diseases, Drugs, 37, 801-870.

Gothoskar, A. V., 2005, Extended release formulation using hydrophilic matrices, Modified Release Forum, Colorcon, Jakarta, 17th May 2005.

Harwood, R. J., 2006, Hydroxypropyl Cellulose, in Rowe, (Ed), Handbook of Pharmaceutical Excipients,

th ed, Pharmaceutical press, London.

Jaimini, M., Rana, A. C. and Tanwar, Y. S. 2007, Formulation and Evaluation of Famotidine Floating Tablets, Current Drug Delivery, 4, 51-55

Nadigoti, J. and Shayeda, 2009, Review Article: Floating Drug Delivery Systems, Int. J. Pharm. Sci. and Nanotech., 2 (3), 595-604.

McQuaid, K. R., 2010, Alimentary Tract, in McPhee, S. J. and Papadakis, M. A., (Eds), Current Medical Diagnosis and Treatment, 49th Ed., 588-589, McGraw-Hill, USA.

Pithavala Y. K, Heizer W. D, Parr A. F, O’Connor-Semmes R. L, and Brouwer K. L. 1998, Use of the Inteli Site capsule to study ranitidin HCl absorption from various sites within the human intestinal tract. Pharm. Res.15:1869–1875.

Rocca, J.G., Omidian, H. and Shah, K., 2003, Progress in Gastroretentive Drug Delivery Systems,Bussiness Br iefing Phar matech, 152, www.touchbriefings.com, 18 Juni 2009.

Rosa, M., Zia H. and Rhodes, T., 1994, Design and testing in vitro of a bioadhesive and floating drug delivery system for oral application, Int.J.Pharm., 105,65-70.

DOI: http://dx.doi.org/10.14499/indonesianjpharm0iss0pp106-114


  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Indonesian J Pharm indexed by:

analytics View My Stats